Collegium Pharmaceutical (COLL) Amortization of Deferred Charges (2014 - 2026)

Collegium Pharmaceutical's Amortization of Deferred Charges history runs 9 years deep, the most recent figure standing at $819000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 40.09% year-over-year to $819000.0 in Q1 2026; TTM through Mar 2026 was $4.3 million, a 15.53% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, down 11.22% from the prior year.
• Amortization of Deferred Charges slipped to $819000.0 in Q1 2026 per COLL's latest filing, from $1.3 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $2.5 million in Q2 2022 and bottomed at $819000.0 in Q1 2026.
• The 5-year median for Amortization of Deferred Charges is $1.4 million (2024), against an average of $1.6 million.
• Across the five-year window, Amortization of Deferred Charges soared 205.91% in 2022 and plunged 48.0% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $2.4 million in 2022, then dropped by 17.62% to $2.0 million in 2023, then declined by 27.46% to $1.4 million in 2024, then declined by 10.39% to $1.3 million in 2025, then plunged by 35.82% to $819000.0 in 2026.
• Per Business Quant, the three latest COLL Amortization of Deferred Charges figures stand at $819000.0 (Q1 2026), $1.3 million (Q4 2025), and $1.1 million (Q3 2025).